相关实验视频

Updated: Jan 12, 2026

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

无管胰岛素与基于云的数据管理平台相结合:来自14765名法国糖尿病患者的现实世界证据

Nathalie Jeandidier¹, Arthur Bagel², Alice Bonin³

¹Service d'Endocrinologie, Diabète, Nutrition, CHRU Strasbourg, Université de Strasbourg, Strasbourg, France.

Diabetes therapy : research, treatment and education of diabetes and related disorders

|November 1, 2025

概括

糖尿病的无管胰岛素使用者表现出适度的葡萄糖控制和良好的安全结果. 观察到持续的使用,这表明研究和改善患者护理的潜力.

科学领域:

内分泌学在内分泌学.
代谢疾病代谢疾病
医疗器械医疗器械

背景情况:

检查儿童,青少年和成人1型 (T1D) 和2型糖尿病 (T2D) 的葡萄糖指标和胰岛素输送模式.
使用无管Omnipod DASH®胰岛素,通过myDiabby Healthcare®数据管理平台 (DMP) 集成连续血糖监测 (CGM).

研究的目的:

通过使用特定的胰岛素系统,分析大量糖尿病患者对葡萄糖控制和胰岛素输送的现实数据.
评估与CGM结合的无管胰岛素治疗相关的有效性和安全结果.

主要方法:

从DMP中提取了17344名用户的时间CGM和胰岛素数据,最初的数据是2020年1月1日之后的.
包括至少有90天的和CGM数据的用户,并在>15.5%的日内>70%的CGM覆盖率.
根据糖尿病类型 (T1D与T2D) 和年龄组进行了分层分析.

主要成果:

分析包括14,757名用户,主要是T1D (93.7%),平均年龄为33岁.
中位时间在范围 (TIR) 为T1D的52.5%和T2D的66.9%;12.6%的T1D和42.8%的T2D用户实现了TIR≥70%.
对于T1D使用者来说,中位时间低于范围 (TBR) 为3.7%;超过90%的所有用户每天消耗<60 IU.

结论:

无管胰岛素的使用者表现出中度的血糖结果和有利的安全概况.
在研究群体中观察到胰岛素系统的持续和持续使用.
像这个DMP这样的大型,高质量的数据库为糖尿病研究和临床实践优化提供了重要的价值.

关键词:

在CGM中,CGM是指CGM.数据管理平台数据管理平台胰岛素可以提供胰岛素.现实世界的数据数据.第1型糖尿病是什么?2 型糖尿病 2 型糖尿病

更多相关视频

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

相关概念视频

Insulin Formulations: Types and Delivery

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...